Antibody Discovery: Cell-Free Protein Synthesis vs CHO Guide

 

Mammalian expression is the gold standard in antibody discovery for detailed kinetic profiling, functional assays, developability, and manufacturing-relevant scale-up. However, early-stage antibody discovery workflows often begin with a much narrower, binary question: Does this specific sequence express as a full-length IgG, and does it bind the target antigen?

 

Cell-free protein synthesis (CFPS) bypasses the timeline of living host cells, compressing the path from digital DNA sequence to physical testing from days to weeks. This enables screening a much wider library of candidates before consuming resources on expensive mammalian hit validation.

 

As generative AI antibody design pipelines continuously spit out thousands of de novo sequences, implementing a high-throughput antibody screening triage layer in the wet lab is the only way to keep physical validation in lockstep with computational scale.

 

While cell-free protein expression has earned its stripes for rapidly producing simple antibody fragments like scFvs, Fabs, and VHH nanobodies^1–3, its application to complex, full-length therapeutic IgGs has historically faced skepticism. This guide dismantles the technical barriers of bacterial cell-free synthesis, debunks the mammalian glycosylation myth in early triage, and reviews the empirical data demonstrating that aglycosylated cell-free antibodies perfectly match the binding affinity and kinetics of traditional CHO controls.

 

What is cell-free protein synthesis in antibody discovery?

 

Cell-free protein synthesis is a method for producing proteins outside living cells. Instead of relying on cell transformation, transfection, culture, harvest, and purification, CFPS uses the molecular machinery of transcription and translation in an open biochemical reaction.

 

Most CFPS systems can be understood as two core modules. The first is the protein synthesis machinery, supplied either through a cellular extract or a reconstituted system^3–4. This includes ribosomes, tRNAs, transcriptional and translational enzymes, and associated factors required to convert genetic templates into protein. The second is the substrate and energy module, which supplies amino acids, nucleotides, salts, cofactors, and energy regeneration components to maintain ATP and GTP availability during the reaction.

 

The open nature of CFPS is what makes it especially useful for difficult proteins. Reaction conditions can be tuned directly, including template ratio, redox environment, ionic strength, pH, cofactors, and folding additives. Auxiliary factors such as disulfide bond isomerases, molecular chaperones, folding enhancers, or membrane-mimicking structures can also be added when needed to improve solubility, folding, or functional activity^5–8.

 

 

 

Why CFPS first gained traction for scFv, Fab, and VHH workflows

 

Cell-free antibody expression first gained attention in fragment-based workflows for good reason. scFvs, Fabs, and VHH/nanobody domains are smaller and structurally simpler than full-length IgGs. VHH domains, for example, are single-domain antibody fragments of approximately 15 kDa and are valued for their stability, solubility, tissue penetration, and ability to access cavity-like epitopes².

 

E. coli CFPS is the most commonly used system in fragment screening due to higher protein yields, faster expression speeds, lower costs, and its maturity as a platform. These advantages make it easier to standardize and automate, rendering it highly suitable for high-throughput screening.

 

Several published workflows show the benefits of CFPS for antibody fragments. Cell-free systems have been used for nanobody generation and functional characterization, rapid antigen-binding fragment production, and high-throughput antibody fragment screening^1–3. In one Nature Communications workflow, researchers combined cell-free DNA template generation, CFPS, and binding measurements to express and profile hundreds of antibody fragments in less than 24 hours³.

 

That body of work establishes an important point: CFPS already has a place in antibody discovery.

 

However, fragment workflows also create a translation step. Antibody fragments are useful for screening, but they are often not the final therapeutic format. In fragment-based discovery workflows, promising sequences must still be reformatted into a full-length IgG before scaled expression and downstream development can begin.

 

Why full-length IgG expression is harder

 

A full-length IgG1 is not simply an oversized antibody fragment. It is a complex, ~150 kDa heterotetramer requiring coordinated heavy-chain (HC) and light-chain (LC) expression, correct quaternary chain pairing, precise structural folding, and the formation of multiple intra- and inter-chain disulfide bonds.

 

The difference is substantial. Single-chain antibody fragments assemble from one polypeptide chain and typically require fewer disulfide constraints. Full-length antibodies require assembly of two heavy chains and two light chains into a disulfide-bonded heterotetramer.

 

Table 1. Key differences between fragment and full-length antibody screening workflows.

Feature	scFv / Fab / VHH workflows	Full-length IgG workflows
Format	Fragment or single-domain binder	Complete therapeutic antibody format
Molecular complexity	Lower	Higher
Chain assembly	One or two chains, depending on format	Two heavy chains and two light chains
Disulfide requirement	Fewer disulfide constraints	Multiple intra- and inter-chain disulfides
Development translation step	Often requires reformatting to IgG	Already screened in IgG format
Key advantage	Fast fragment discovery	Earlier triage in a therapeutically relevant format

 

This structural gap explains why using an E. coli cell-free systems for therapeutic antibody discovery raises two questions:

• Can E. coli CFPS assemble a full-length IgG?
  IgG assembly requires correct heavy-chain/light-chain pairing and disulfide-bonded heterotetramer formation.
• Does lack of mammalian glycosylation compromise binding data?
  E. coli systems do not naturally produce mammalian Fc glycans, raising concerns about whether the material can support reliable antibody binding assessment.

 

While mammalian cell-free systems exist that can natively introduce glycans, they are fundamentally limited by scalability and high costs. The true operational prize for high-throughput screening lies in engineering E. coli CFPS to unlock unmatched speed and cost-efficiency.

 

So, for the remainder of the blog, we will address both questions.

 

Full-length IgG1 assembly in E. coli CFPS

 

Recent biochemistry developments show that E. coli CFPS reaction environments can be precisely customized to express full-length antibodies^5–7. Incorporating the periplasmic chaperone DsbC, adjusting the GSH/GSSG redox buffer balance, and introducing specialized molecular chaperones (like the DnaK mix) have been shown to drastically enhance the solubility of synthesized heavy and light chains and catalyze correct thiol-disulfide exchange, driving efficient full-length assembly.

 

Nuclera has engineered a proprietary E. coli CFPS system optimized to express fully assembled, full-length therapeutic IgGs from either E. coli or CHO codon-optimized linear DNA sequences within 24 hours.

 

To verify that CFPS can produce full-length IgG, we showcase four therapeutically relevant antibodies (Trastuzumab, Cetuximab, Ipilimumab, and Nivolumab) produced using CFPS and subjected to side-by-side reduced and non-reduced SDS-PAGE analysis (Figure 2). Under reducing conditions, the intermolecular disulfide bonds are broken, resolving clear, isolated heavy chain (~50 kDa) and light chain (~25 kDa) bands. Under non-reducing conditions, the intact, fully assembled IgG1 resolves as a single, clean band at the expected molecular weight of ~150 kDa.

 

This addresses the first technical question: E. coli CFPS can produce full-length IgG1 when the reaction system is engineered to support folding and disulfide formation.

 

 

CFPS IgG1 binding kinetics closely track CHO controls

 

The definitive metric for validating a cell-free antibody screening platform is its kinetic concordance with mammalian produced equivalent antibodies, proving that the antigen-binding interface remains uncompromised.

 

We benchmarked CFPS-produced purified IgG1 antibodies against CHO-made controls using trastuzumab, nivolumab, cetuximab, and ipilimumab. SPR-derived K_D, K_on, and K_off values from CFPS-produced antibodies aligned closely with CHO controls, supporting preservation of the antigen-binding interface in the cell-free format. Therefore, CFPS-derived antibodies can be used to produce binding profiles predictive of CHO supporting binding-driven hit ranking.

 

Together, these SPR data support the use of CFPS-derived antibodies for binding-driven hit ranking before committing every candidate to mammalian expression.

 

 

Table 2. Comparing KD values for CHO made and CFPS made antibodies.

Antibody	Target	CHO-made KD	CFPS-made KD
Trastuzumab	HER2	1.24 nM	1.18 nM
Nivolumab	PD-1	2.54 nM	2.02 nM
Cetuximab	EGFR	0.25 nM	0.12 nM

 

Does antibody glycosylation matter for binding affinity?

 

Glycosylation matters in antibody biology. Fc glycans are central to Fc receptor engagement, ADCC, CDC, pharmacology, safety, and product quality⁹. Any antibody moving toward therapeutic development still needs glycan-aware mammalian confirmation.

 

But early target-binding triage asks a narrower question: Do you need mammalian glycosylation to determine whether an antibody binds its antigen?

 

For many standard antigen-binding assays, the target-binding interface is driven primarily by the Fab and variable domains, not the Fc glycan. There are important exceptions. Variable-domain or Fab glycans can occur and may influence antigen binding, stability, or affinity in some contexts¹⁰. That means sequence context still matters.

 

Our Trastuzumab dataset directly addresses this objection (Figure 4). Glycoprotein staining confirms the presence of glycosylated heavy chains in CHO-produced Trastuzumab and completely aglycosylated heavy chains in CFPS-produced Trastuzumab. Despite this structural difference, ELISA EC₅₀ values and curve shapes remain comparable between formats (CHO EC50 = 0.662 pM vs. Cell-free = 0.994 pM), indicating that glycosylation differences do not compromise binding-based hit validation.

 

This data, alongside the previous SPR data, addresses the second technical question: Aglycosylated CFPS-made antibodies produce binding data predictive of CHO-made antibodies compromise binding data?

 

The practical takeaway is precise: Glycosylation is critical for later-stage antibody biology. It is not necessarily required for early target-binding screening.

 

 

How cell-free antibody screening fits AI antibody discovery

 

AI antibody design can rapidly propose large candidate sets, but physical validation still determines which antibodies bind.

 

This creates a mismatch: the computational design step scales digitally, while the Build and Test phases remain constrained by expression timelines, purification capacity, assay queues, and downstream costs.

 

A CFPS-first workflow helps restore the experimental feedback loop without turning CHO into the first gate for every unverified sequence. A practical cell-free antibody triage workflow looks like this:

1. Start with VH/VL sequences and target antigen.
2. Prepare expression-ready DNA.
3. Express full-length IgG1 using CFPS.
4. Run binary expression and binding screening.
5. Perform SPR on prioritized binders.
6. Advance confirmed candidates into CHO expression and downstream characterization.

 

This workflow gives AI and discovery teams earlier access to both positive and negative experimental data. Binders can move forward, non-binders can be removed before consuming precious CHO capacity, and the resulting truth tables can be fed directly back into machine learning models to guide the next round of design.

 

 

Myth vs reality: cell-free protein synthesis for antibody discovery

 

Table 3. Myth and reality de-bunk.

Myth	Reality
CFPS is only useful for simple proteins or antibody fragments.	CFPS has already been used for scFv, Fab, and VHH workflows, and Nuclera’s validation data show full-length IgG1 assembly in an engineered E. coli CFPS system.
E. coli CFPS cannot support reliable antibody folding.	CFPS reaction conditions can be engineered with redox control, disulfide isomerases, and chaperones to support disulfide-rich proteins, including IgG formats.
Lack of mammalian glycosylation makes CFPS antibodies unsuitable for screening.	Glycosylation remains essential for downstream Fc biology, but Nuclera’s aglycosylated CFPS antibodies produced comparable early binding readouts to glycosylated CHO controls.
You need CHO expression before you can trust early binding data.	CHO remains essential later, but CFPS can provide early expression, binding, and kinetic data to decide which candidates deserve CHO.

 

Practical decision guide: when to use CFPS vs CHO

 

The right question is not “CFPS or CHO?” The right question is “what decision are you trying to make?”

 

Table 4. Use cases for CFPS or CHO first workflows.

Use case	Use CFPS first?	Use CHO first?
Determine whether a candidate expresses as full-length IgG1.	Yes	Not necessary
Identify binders and non-binders from a broad candidate pool	Yes	Not necessary
Generate KD, Kon, and Koff	Yes	Not necessary
Assess Fc effector function	No	Yes
Generate manufacturing-relevant material	No	Yes
Confirm final therapeutic candidate behavior	No	Yes

 

Can CFPS replace CHO for early binding data?

 

For final therapeutic development, CHO expression remains essential for downstream confirmation, Fc biology, glycan-dependent function, functional assays, developability, and manufacturing-relevant assessment.

 

For early binding triage, CFPS enables you to determine which antibodies express, bind, and deserve deeper investment, quicker and more cost-effectively.

 

Nuclera’s E. coli CFPS data show full-length IgG1 assembly, comparable ELISA binding, and SPR-derived kinetics that closely track CHO-produced controls across multiple therapeutically relevant antibodies. Together, these results support CFPS as a rapid, scalable triage step before investing in mammalian expression.

 

The result is a more efficient antibody discovery workflow: screen broader libraries earlier, eliminate non-binders sooner, and reserve high-cost downstream biology for candidates with experimental evidence behind them.

 

Stop waiting for CHO just to get early binding data

 

If your antibody discovery workflow is generating more candidates than your mammalian expression pipeline can validate, add an upstream triage layer.

 

Nuclera’s Cell-Free Antibody Screening Service converts antibody sequences into early expression, binding, and kinetic data from 14 business days, helping teams identify non-binders before committing every candidate to mammalian expression.

 

Download the white paper: Trust Your Triage: How Cell-Free Antibodies Predict CHO Binding Kinetics

 

References

 

1. Stech, M. & Kubick, S. Cell-free synthesis meets antibody production: a review. Antibodies 4, 12–33 (2015).
2. Haueis, L. H., Stech, M. & Kubick, S. A cell-free expression pipeline for the generation and functional characterization of nanobodies. Front. Bioeng. Biotechnol. 10, 896763 (2022).
3. Hunt, A. C. et al. A rapid cell-free expression and screening platform for antibody discovery. Nat. Commun. 14, 3897 (2023).
4. Silverman, A. D., Karim, A. S. & Jewett, M. C. Cell-free gene expression: an expanded repertoire of applications. Nat. Rev. Genet. 21, 151–170 (2020).
5. Yin, G. et al. Aglycosylated antibodies and antibody fragments produced in a scalable in vitro transcription-translation system. mAbs 4, 217–225 (2012).
6. Cai, Q. et al. A simplified and robust protocol for immunoglobulin expression in Escherichia coli cell-free protein synthesis systems. Biotechnol. Prog. 31, 823–831 (2015).
7. Murakami, S., Matsumoto, R. & Kanamori, T. Constructive approach for synthesis of a functional IgG using a reconstituted cell-free protein synthesis system. Sci. Rep. 9, 671 (2019).
8. González-Ponce, K. S. et al. Cell-free systems and their importance in the study of membrane proteins. J. Membr. Biol. 258, 15–28 (2025).
9. Mimura, Y. et al. Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy. Protein Cell 9, 47–62 (2018).
10. van de Bovenkamp, F. S. et al. Variable domain N-linked glycans acquired during antigen-specific immune responses can contribute to immunoglobulin G antibody stability. Front. Immunol. 9, 740 (2018).